7.3 Hemoglobinopathies, Thalassemias & Paroxysmal Nocturnal Hemoglobinuria

ABIM Internal Medicine Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 0: The ABIM Exam, Blueprint & Study Strategy

0.1 Exam Format, Question Types & the 2026 Blueprint 0.2 Eligibility, Registration, Fees & Exam-Day Logistics 0.3 Scoring, the Passing Standard & Score Reports 0.4 Building a Blueprint-Weighted Study Plan

2 Chapter 1: Cardiovascular Disease (14% of Exam)

1.1 Ischemic Heart Disease & Acute Coronary Syndromes 1.2 Antithrombotic Therapy, Secondary Prevention & Mechanical Complications of MI 1.3 Atrial Fibrillation, Atrial Flutter & Stroke Prevention 1.4 Supraventricular Tachycardias, Ventricular Arrhythmias & Bradycardias 1.5 Heart Failure: Classification, Staging & Guideline-Directed Medical Therapy 1.6 Device Therapy, HFpEF & the Cardiomyopathies 1.7 Valvular Heart Disease & Endocarditis Prophylaxis 1.8 Pericardial Disease & Acute Aortic Syndromes 1.9 Hypertension: Classification, Diagnosis & Secondary Causes 1.10 Hypertensive Crises & Dyslipidemia 1.11 Adult Congenital Heart Disease & Coarctation of the Aorta 1.12 Syncope: Reflex, Orthostatic & Cardiac Causes 1.13 Cardiac Physical Examination, Murmurs & Antithrombotic Selection

3 Chapter 2: Endocrinology, Diabetes & Metabolism (9% of Exam)

2.1 Diabetes Mellitus: Diagnosis, Glycemic Targets & Pharmacotherapy 2.2 Insulin Therapy, Hyperglycemic Emergencies & Chronic Complications 2.3 Thyroid Function Testing & Hypothyroidism 2.4 Thyrotoxicosis, Thyroid Storm & Thyroid Nodules 2.5 Adrenal & Pituitary Disorders 2.6 Hypercalcemia, Hypocalcemia & Disorders of Mineral Metabolism 2.7 Osteoporosis & Paget Disease of Bone 2.8 Ovarian, Testicular & Reproductive Endocrine Disorders 2.9 Hypoglycemia, Endocrine Tumors, Polyglandular Syndromes & Severe Hypertriglyceridemia

4 Chapter 3: Gastroenterology & Hepatology (9% of Exam)

3.1 Esophageal Disease 3.2 Stomach & Duodenal Disease and Gastrointestinal Hemorrhage 3.3 Inflammatory Bowel Disease 3.4 Celiac Disease & Irritable Bowel Syndrome 3.5 Diverticular Disease & Colorectal Cancer Screening 3.6 Viral Hepatitis, Steatotic & Alcohol-Associated Liver Disease 3.7 Cirrhosis & the Complications of Portal Hypertension 3.8 Acute Pancreatitis 3.9 Chronic Pancreatitis & Biliary Tract Disease 3.10 Inherited, Autoimmune & Drug-Induced Liver Disease 3.11 Small Intestinal Disease, Ischemia & Gastrointestinal Complications of HIV

5 Chapter 4: Infectious Disease (9% of Exam)

4.1 Lower Respiratory Tract Infections & Sepsis Syndromes 4.2 Viral Respiratory Pathogens & Tuberculosis 4.3 Central Nervous System Infections 4.4 Skin, Soft Tissue, Bone & Joint Infections 4.5 Infective Endocarditis & Cardiovascular Infection 4.6 Clostridioides difficile & Catheter-Related Bloodstream Infection 4.7 HIV Diagnosis, Antiretroviral Therapy & Prevention 4.8 Opportunistic Infections & Sexually Transmitted Infections 4.9 Fever of Unknown Origin, Neutropenic Fever & Toxic Shock 4.10 Travel-Related Illness, Vector-Borne Disease & Outbreaks 4.11 Infection Prevention, Nosocomial Infection & Postexposure Prophylaxis 4.12 Rheumatic Fever, Poststreptococcal Disease, Enteric & Hepatic Infections

6 Chapter 5: Pulmonary Disease (9% of Exam)

5.1 COPD: Diagnosis, GOLD Classification & Initial Pharmacotherapy 5.2 Interventions That Reduce COPD Mortality & Exacerbation Management 5.3 Asthma: Diagnosis, Stepwise Therapy & Status Asthmaticus 5.4 Interstitial Lung Disease & Idiopathic Pulmonary Fibrosis 5.5 Sarcoidosis, Hypersensitivity Pneumonitis & Occupational Lung Disease 5.6 Pulmonary Embolism: Diagnosis, Risk Stratification & Anticoagulation 5.7 Pulmonary Hypertension & Sleep-Disordered Breathing 5.8 Acute Respiratory Distress Syndrome & Mechanical Ventilation 5.9 Pleural Disease, Empyema & Pneumothorax 5.10 Bronchiectasis, Cystic Fibrosis & Restrictive Lung Disease 5.11 Evaluation of Cough, Dyspnea, Hemoptysis & the Solitary Pulmonary Nodule

7 Chapter 6: Rheumatology & Orthopedics (9% of Exam)

6.1 Rheumatoid Arthritis: Diagnosis & Systemic Manifestations 6.2 Antirheumatic Pharmacotherapy & the Spondyloarthropathies 6.3 Gout: Pathophysiology & Acute Management 6.4 Urate-Lowering Therapy & Calcium Pyrophosphate Deposition Disease 6.5 Osteoarthritis 6.6 Systemic Lupus Erythematosus 6.7 Systemic Sclerosis, Sjogren Syndrome & Inflammatory Myopathies 6.8 The Vasculitides 6.9 Regional Musculoskeletal Syndromes, Back Pain & Sports Injuries 6.10 Other Primary Rheumatic Disorders & Mixed Connective Tissue Disease 6.11 Osteonecrosis & Metabolic Bone Disease

8 Chapter 7: Hematology (6% of Exam)

7.1 Approach to Anemia & the Microcytic Anemias 7.2 Macrocytic, Normocytic & Hemolytic Anemias 7.3 Hemoglobinopathies, Thalassemias & Paroxysmal Nocturnal Hemoglobinuria 7.4 Platelet Disorders, Thrombocytopenia & the Bleeding Patient 7.5 Coagulation Factor Disorders, Thrombophilia & Anticoagulant Reversal 7.6 Acute Leukemias, Chronic Leukemias & Myeloproliferative Neoplasms 7.7 Lymphomas & Plasma Cell Disorders 7.8 Myelodysplastic Syndrome, Myeloproliferative Neoplasms & Porphyria 7.9 Transfusion Medicine & Late Complications of Transplantation

9 Chapter 8: Medical Oncology (6% of Exam)

8.1 Breast, Lung, Colorectal & Prostate Cancer 8.2 Oncologic Emergencies 8.3 Genitourinary & Gynecologic Malignancies 8.4 Head and Neck, Bone & Soft Tissue Cancer and Cancer of Unknown Primary 8.5 Complications of Cancer & Its Treatment 8.6 Cancer Prevention, Survivorship & Psychosocial Care

10 Chapter 9: Nephrology & Urology (6% of Exam)

9.1 Acute Kidney Injury: Staging, Etiology & Urine Microscopy 9.2 Glomerular Disorders & Nephrotic Syndrome 9.3 Nephritic Syndromes, RPGN & Indications for Renal Replacement Therapy 9.4 Chronic Kidney Disease: Staging & Progression Retardation 9.5 Complications of Chronic Kidney Disease: Anemia, CKD-MBD & Acidosis 9.6 Hyponatremia, Hypernatremia & Water Balance 9.7 Potassium Disorders & Systematic Acid-Base Analysis 9.8 Renal Tubular Acidosis & Nephrolithiasis 9.9 Prostate Disorders, Urinary Incontinence & Other Urologic Conditions 9.10 Cystic Kidney Disease, Obstructive Uropathy, Tubulointerstitial Disease & Hematuria

11 Chapter 10: Neurology (4% of Exam)

10.1 Acute Ischemic Stroke: Syndromes & Reperfusion 10.2 Transient Ischemic Attack, Secondary Prevention & Hemorrhagic Stroke 10.3 Headache & Facial Pain 10.4 Seizures, Epilepsy & Movement Disorders 10.5 Multiple Sclerosis & Neuromuscular Junction Disorders 10.6 Motor Neuron Disease & Acute Peripheral Neuropathy 10.7 Cranial Neuropathies & Neuro-Ophthalmology 10.8 Peripheral Neuropathies, CNS Tumors & Other Neurologic Disorders

12 Chapter 11: Psychiatry & Behavioral Health (4% of Exam)

11.1 Major Depressive Disorder & Medical Mimics 11.2 Antidepressant Pharmacotherapy & Treatment-Resistant Depression 11.3 Bipolar Disorder, Mood Stabilizers & Lithium Toxicity 11.4 Anxiety, Stress-Related & Obsessive-Compulsive Disorders 11.5 Alcohol Use Disorder & Withdrawal 11.6 Pharmacotherapy for Alcohol & Opioid Use Disorder 11.7 Toxidromes, Psychiatric Emergencies & Suicide Risk Assessment 11.8 Psychotic, Somatic Symptom, Factitious & Personality Disorders 11.9 Eating Disorders, Sleep Disorders & Sexual Health

13 Chapter 12: Dermatology (3% of Exam)

12.1 Dermatitis, Papulosquamous & Inflammatory Dermatoses 12.2 Acne, Rosacea & Cutaneous Infections 12.3 Herpes Zoster & Autoimmune Blistering Diseases 12.4 Nodules, Tumors & Cutaneous Oncology 12.5 Dermatologic Emergencies & Severe Cutaneous Adverse Reactions 12.6 Pigment Disorders, Alopecia, Nail Disease & Photosensitivity 12.7 Vascular Dermatoses, Environmental Injury & Cutaneous Signs of Systemic Disease

14 Chapter 13: Obstetrics & Gynecology / Women's Health (3% of Exam)

13.1 Contraception, Preconception Care & Teratogenicity 13.2 Hypertensive Disorders of Pregnancy & Gestational Diabetes 13.3 Thyroid Disease & Venous Thromboembolism in Pregnancy 13.4 Menopause & Menopausal Hormone Therapy 13.5 Abnormal Uterine Bleeding, Endometrial Disease & Gynecologic Cancer Screening 13.6 Breast Disorders & Diseases of the Vulva and Vagina 13.7 Menstrual Disorders, Fibroids, Endometriosis & Early Pregnancy Complications

15 Chapter 14: Geriatric Syndromes (3% of Exam)

14.1 Comprehensive Geriatric Assessment & Frailty 14.2 Falls, Gait Assessment & Polypharmacy 14.3 Urinary Incontinence & Pressure Injuries in Older Adults 14.4 Mild Cognitive Impairment, Dementia & Its Subtypes 14.5 Delirium & the Pharmacotherapy of Cognitive Disorders 14.6 Palliative Care, Hospice & Advance Care Planning 14.7 Chronic Wounds, Nutrition, Swallowing, Constipation & Hip Fracture 14.8 Sensory Impairment, Dizziness, Elder Mistreatment & Care Settings

16 Chapter 15: Allergy & Immunology (2% of Exam)

15.1 Anaphylaxis: Recognition & Emergency Management 15.2 Urticaria & Angioedema 15.3 Drug Allergy, Desensitization & Adult Immunodeficiency 15.4 Food Allergy, Insect Venom Hypersensitivity, Serum Sickness & Contrast Reactions 15.5 Rhinitis, Conjunctivitis, Eosinophilic & Mast Cell Disorders

17 Chapter 16: Preventive Medicine, Immunization & Clinical Epidemiology

16.1 The USPSTF Framework & Evidence-Based Cancer Screening 16.2 Cardiovascular & Metabolic Screening and Primary Prevention 16.3 Adult Immunization & Vaccines in Special Populations 16.4 Clinical Epidemiology, Biostatistics & Study Design

18 Chapter 17: Miscellaneous - Ethics, Patient Safety & Quality Improvement (2% of Exam)

17.1 Principles of Bioethics & Decisional Capacity 17.2 Informed Consent, Treatment Refusal & Special Scenarios 17.3 Surrogate Decision-Making, Advance Directives & Confidentiality 17.4 Patient Safety Science, Medical Error & Diagnostic Reasoning 17.5 Quality Improvement Methods, Health Disparities & Health Equity

19 Chapter 18: Perioperative Medicine & Medical Consultation

18.1 Preoperative Cardiovascular Risk Assessment 18.2 Preoperative Pulmonary Risk & Perioperative Medication Management 18.3 Perioperative Anticoagulation, Bridging & Postoperative Complications

20 Chapter 19: Ophthalmology (1% of Exam)

19.1 The Acute Red Eye & Ophthalmic Emergencies 19.2 Painless Vision Loss & Chronic Ophthalmic Disease 19.3 Uveitis, Scleritis & Orbital Disease

21 Chapter 20: Otolaryngology & Dental Medicine (1% of Exam)

20.1 Dizziness, Vertigo & Epistaxis 20.2 Ear Disorders, Hearing Loss & Upper Respiratory Infections 20.3 Oral Cavity, Salivary Gland, Laryngeal & Taste and Smell Disorders

7.3 Hemoglobinopathies, Thalassemias & Paroxysmal Nocturnal Hemoglobinuria

Key Takeaways Explain This Topic AI

Thalassemias and hemoglobinopathies are the two enumerated topics within the hemoglobinopathy blueprint subsection.

Thalassemia trait shows microcytosis with a normal or elevated red blood cell count and a normal red cell distribution width, unlike iron deficiency.

Acute chest syndrome in sickle cell disease requires prompt transfusion, antibiotics and respiratory support and is a leading cause of death.

Hydroxyurea reduces vaso-occlusive crises, acute chest syndrome and mortality by raising fetal hemoglobin.

Paroxysmal nocturnal hemoglobinuria produces complement-mediated intravascular hemolysis with thrombosis at unusual sites and is diagnosed by flow cytometry rather than by the historical sucrose or acid hemolysis tests.

Last updated: August 2026

• 1. Microangiopathic Hemolytic Anemia (MAHA) & PNH
• Microangiopathic Hemolytic Anemia (MAHA)

MAHA results from mechanical fragmentation of erythrocytes passing through microvascular thrombi or fibrin networks in arterioles and capillaries. Peripheral blood smear demonstrates schistocytes (helmet cells, fragmented erythrocytes) comprising > 1.0% of total RBCs. Primary causes include Thrombotic Thrombocytopenic Purpura (TTP), Hemolytic Uremic Syndrome (HUS), Disseminated Intravascular Coagulation (DIC), malignant hypertension, and scleroderma renal crisis.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Pathophysiology: Acquired somatic mutation in the X-linked PIGA gene within hematopoietic stem cells, resulting in deficient synthesis of the glycosylphosphatidylinositol (GPI) anchor . Without GPI anchors, erythrocytes lack membrane-bound complement regulatory proteins CD55 (Decay-Accelerating Factor) and CD59 (Membrane Attack Complex Inhibitor / MIRL) , leading to uncontrolled, chronic alternative complement-mediated intravascular lysis.

Classic Clinical Triad:

Coombs-Negative Intravascular Hemolytic Anemia: Episodic dark/cola-colored morning urine (hemoglobinuria), fatigue, chronic renal hemosiderosis.

Severe Thrombophilia at Atypical Venous Sites: Intra-abdominal veins ( Budd-Chiari syndrome / hepatic vein thrombosis , portal/mesenteric vein thrombosis), cerebral sagittal sinus thrombosis, and dermal veins.

Pancytopenia / Bone Marrow Failure: Aplastic anemia-PNH overlap syndrome, smooth muscle dystonias (esophageal spasms, severe abdominal pain, erectile dysfunction) due to free hemoglobin scavenging nitric oxide (NO).

Diagnostic Gold Standard: High-sensitivity multi-parameter flow cytometry on peripheral blood granulocytes and erythrocytes demonstrating absence or reduction of CD55, CD59, and GPI-anchored protein marker FLAER (fluorescently labeled aerolysin).

Management:

Terminal Complement C5 Inhibitors: Eculizumab (IV every 2 weeks) or long-acting Ravulizumab (IV every 8 weeks) blocks cleavage of C5 to C5a/C5b, preventing MAC formation, dramatically reducing intravascular hemolysis, transfusion dependence, and thrombotic events.

Mandatory Prophylaxis: All patients must receive Meningococcal vaccinations (MenACWY and MenB) at least 2 weeks prior to starting C5 inhibitors due to increased risk of invasive Neisseria meningitidis infections (supplement with oral penicillin/ciprofloxacin prophylaxis if urgent treatment is required before vaccine takes effect).

2. Hemoglobinopathies: Sickle Cell Disease (SCD)

Sickle cell disease (HbSS) results from a homozygous missense mutation (Glu6Val substitution on codon 6 of the β \beta β -globin gene), causing polymerization of deoxygenated HbS, erythrocyte sickling, chronic extravascular/intravascular hemolysis, and microvascular vaso-occlusion.

Major Acute Complications and Management

Complication Pathophysiology & Presentation Diagnostic Findings Evidence-Based Management

Vaso-Occlusive Pain Crisis (VOC) Microvascular occlusion by sickled RBCs and leukocyte adhesion; severe bone, back, chest, or joint pain Normal imaging, clinical diagnosis of exclusion Rapid, individualized IV opioids (Morphine, Hydromorphone), oral/IV hydration (avoid fluid overload), maintain oxygenation

Acute Chest Syndrome (ACS) Pulmonary vaso-occlusion, fat embolism, or infection ( Mycoplasma, Chlamydia, S. pneumoniae ); fever, chest pain, tachypnea, hypoxemia, cough New pulmonary infiltrate on chest radiograph Empiric IV Ceftriaxone + oral Azithromycin, supplemental O2, incentive spirometry q2h; Simple transfusion for mild-moderate ACS; Automated Red Cell Exchange Transfusion (Erythrocytapheresis) for severe hypoxemia (PaO2 < 60 mmHg or SpO2 < 90% on high-flow O2), neurological deficits, or rapid progression to target HbS < 30% and Hb ~10 g/dL

Aplastic Crisis Transient cessation of erythropoiesis caused by Parvovirus B19 infection of erythroid precursors Severe acute drop in Hb with profound reticulocytopenia (RI < 0.5%, retics near 0%) Supportive RBC transfusions until marrow recovers (usually 7–14 days); droplet isolation in hospital

Splenic Sequestration Crisis Massive pooling of RBCs within the red pulp of the spleen; presents with sudden pallor, tachycardia, left upper quadrant pain, and acute splenomegaly Severe anemia, marked reticulocytosis , rapid splenic enlargement, hypovolemic shock Emergent crystalloid resuscitation, careful simple RBC transfusion (avoid over-transfusion as trapped RBCs can re-enter circulation); splenectomy after stabilization

Acute Ischemic Stroke Large-vessel intracranial occlusion (internal carotid, middle cerebral) Brain MRI / MRA Emergent automated exchange transfusion to lower HbS < 30%; long-term chronic transfusion therapy to maintain HbS < 30%

Disease-Modifying Therapies in Sickle Cell Disease

Hydroxyurea (First-line): Ribonucleotide reductase inhibitor that stimulates HbF (Fetal Hemoglobin) synthesis, reduces intracellular HbS concentration, lowers leukocyte/platelet counts, and decreases VOC frequency, ACS episodes, and all-cause mortality. Indicated for all patients with HbSS aged ≥ 9 months or adults with ≥ 3 VOCs/year, history of ACS, or severe chronic anemia. Titrate to maximum tolerated dose based on ANC (target ANC 1,500–3,000/mcL; hold if ANC < 1,000 or platelets < 80,000). Teratogenic (hold 3 months prior to conception).

L-Glutamine: Reduces oxidative stress in RBCs; reduces frequency of VOC and hospitalizations.

Voxelotor: HbS oxygen affinity modulator; binds HbS and stabilizes the oxygenated state, inhibiting deoxygenation-induced polymerization and reducing hemolysis.

Crizanlizumab: Monoclonal antibody targeting P-selectin on activated vascular endothelial cells and platelets; blocks multicellular adhesion and reduces pain crisis frequency.

Infection Prophylaxis: Functional asplenia (Howell-Jolly bodies on smear) begins in infancy due to recurrent splenic infarctions. Mandates: Daily oral Penicillin VK prophylaxis until age 5 , comprehensive vaccination against encapsulated organisms ( PCV20 / PPSV23 pneumococcal, MenACWY, MenB, and H. influenzae type b ), and immediate empiric IV Ceftriaxone for any temperature ≥ 38.5°C.

Sections you finish are checked off in the contents.

• Up Next
• 7.4 Platelet Disorders, Thrombocytopenia & the Bleeding Patient
• Continue learning